Cargando…

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers

PURPOSE: Studies have demonstrated an association between quantity of circulating tumor DNA (ctDNA) and poorer survival. We investigated the relationship between percent ctDNA (%ctDNA), total number of ctDNA alterations, and overall survival (OS) in liquid biopsies. MATERIALS AND METHODS: Overall, 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, Peter, Khagi, Yulian, Riviere, Paul, Goodman, Aaron, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450932/ https://www.ncbi.nlm.nih.gov/pubmed/32923910 http://dx.doi.org/10.1200/PO.19.00204

Ejemplares similares

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
por: Pham, Timothy V., et al.
Publicado: (2021)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
por: Nikanjam, Mina, et al.
Publicado: (2020)

Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible
por: Jensen, Taylor J., et al.
Publicado: (2021)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020)

Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy
por: Dhani, Harmeet, et al.
Publicado: (2023)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
por: Lakatos, Eszter, et al.
Publicado: (2021)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET)
por: Chang, Geraldine H., et al.
Publicado: (2018)

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
por: Boichard, Amélie, et al.
Publicado: (2017)

DNA copy number motifs are strong and independent predictors of survival in breast cancer
por: Pladsen, Arne V., et al.
Publicado: (2020)

Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service
por: Parsons, Henrique A., et al.
Publicado: (2012)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal
por: Janku, Filip, et al.
Publicado: (2013)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
por: Wang, Jie, et al.
Publicado: (2023)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies
por: Debattista, Jessica, et al.
Publicado: (2023)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Correction to “Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology”
por: Wang, Jie, et al.
Publicado: (2023)

Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting
por: Kato, Shumei, et al.
Publicado: (2022)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

Click chemistry, 3D-printing, and omics: the future of drug development
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Fool’s gold, lost treasures, and the randomized clinical trial
por: Stewart, David J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2bmhdr49d2figatm33i0tic2l9